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Background: The aim of this study was to analyze the expression of protein tyrosine kinase 6 (PTK6) in
nasopharyngeal carcinoma (NPC) samples, and to identify whether PTK6 can serve as a biomarker for the diagnosis
and prognosis of NPC.
Methods: We used quantitative RT-PCR and Western blotting analysis to detect mRNA and protein expression of
PTK6 in NPC cell lines and immortalized nasopharyngeal epithelial cell lines. 31 NPC and 16 non-tumorous
nasopharyngeal mucosa biopsies were collected to detect the difference in the expression of mRNA level of PTK6
by quantitative RT-PCR. We also collected 178 NPC and 10 normal nasopharyngeal epithelial cases with clinical
follow-up data to investigate the expression of PTK6 by immunohistochemistry staining (IHC). PTK6 overexpression
on cell growth and colony formation ability were measured by the method of cell proliferation assay and colony
formation assay.
Results: The expression of PTK6 was higher in most of NPC cell lines at both mRNA and protein levels than in
immortalized nasopharyngeal epithelial cell lines (NPECs) induced by Bmi-1 (Bmi-1/NPEC1, and Bmi-1/NPEC2). The
mRNA level of PTK6 was high in NPC biopsies compared to non-tumorous nasopharyngeal mucosa biopsies. IHC
results showed the expression of PTK6 was significantly correlated to tumor size (P<0.001), clinical stage (P<0.001),
and metastasis (P=0.016). The patients with high-expression of PTK6 had a significantly poor prognosis compared to
those of low-expression (47.8% versus 80.0%, P<0.001), especially in the patients at the advanced stages (42.2%
versus 79.1%, P<0.001). Multivariate analysis indicated that the level of PTK6 expression was an independent
prognostic factor for the overall survival of patients with NPC (P <0.001). Overexpression of PTK6 in HNE1 cells
enhanced the ability of cell proliferation and colony formation.
Conclusions: Our results suggest that high-expression of PTK6 is an independent factor for NPC patients and it
might serve as a potential prognostic biomarker for patients with NPC.
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Nasopharyngeal carcinoma (NPC) is not a common
tumor in most parts of the world, but there is a high in-
cidence in certain areas of southern China, South-Asia
and North Africa [1,2]. Epstein-Barr virus (EBV) infec-
tion, genetic susceptibility and environmental carcino-
gens are all believed to be the etiologic factors
associated with NPC [3]. NPC is different from other
head and neck malignancies, because of its highly inva-
sive and metastatic features [4]. Most patients can be
cured when they were diagnosed and treated at early
stages since primary NPC is sensitive to radiotherapy.
However, at the advanced stages, distant metastasis is
the main cause of treatment failure [5,6].
By now, clinical TNM (Tumor, Node, Metastasis) sta-
ging is often used to determine the prognosis of NPC
patients. However, the NPC patients at the same clinical
stage usually have different clinical outcomes. It is sug-
gested that TNM staging is deficient in predicting the
prognosis of NPC accurately [7,8]. With the develop-
ment of biomedical research, some molecular bio-
markers have been identified to be associated with NPC
prognosis, such as plasma EBV DNA, serum amyloid
protein A (SAA), sailic acid (SA), EGFR and CENP-H.
[9-14].
Protein tyrosine kinase 6 (PTK6), also known as the
breast tumor kinase (BRK), is an intracellularly non-
receptor Src-related tyrosine kinase [15,16]. It was ini-
tially cloned from a metastatic breast tumor [17]. The
PTK6 gene is located in chromosome 20q 13.3-13.4 and
consists of 8 exons. It is composed of Src homology 2
(SH2) domain, Src homology 3 (SH3) domain, and pro-
tein kinase domain. Since PTK6 lacks myristoylation and
palmitoylation signals, the subcellular localization be-
comes greater flexibility. The expression of PTK6 has
been found in normal differentiated epithelial cells in-
cluding esophagus [18], prostate [19], gastrointestinal
tract [20,21], skin [22,23], oral epithelium [24], and lym-
phocytes [25]. It is reported that PTK6 can negatively
regulate epithelial cell growth and induce apoptosis in
normal intestine [26,27]. It has also been reported that
PTK6 can induce apoptosis of the epithelial cells of the
intestine and skin by DNA damage and serum derivation
[28]. Stephanie Ma et al. found that PTK6 may be an
important tumor suppressor in esophageal squamous
cell carcinoma development. They also found the down-
regulation of PTK6 could promote tumorigenicity and
metastasis [18]. However, over-expression of PTK6 is a
common phenomenon in a variety of epithelial tumors,
such as breast cancer [15,29,30], ovarian cancer [31],
colon cancer [20], head and neck cancer [32], non-small
cell lung cancer (NSCLC) [33], and metastatic melanoma
[34]. For instance, the elevated expression of PTK6 was
detected in breast cancer cell lines and more than 65%primary breast cancers, but was undetectable or at a low
level in normal mammary tissue and benign lesions
[29,30]. Over-expression of PTK6 was shown to increase
proliferation, anchorage-independent growth, cell migra-
tion, and tumor growth in many kinds of breast cancer
model system, while knocking-down of PTK6 leaded to
the opposite results [15]. Also, PTK6 gene was amplified
at low levels in primary ovarian cancer and its protein
level was highly expressed in the majority of high-grade
serous carcinomas and ovarian cancer cell lines but not
the normal ovary [31]. Moreover, PTK6 high mRNA ex-
pression has been reported in the cancers of the bladder
[35], pancreas [36], and gastric cancer [37], but its protein
expression and functions have not been validated in these
cancers. Many studies have shown that PTK6 play differ-
ent roles in normal and cancer epithelia, suggesting that
the function of PTK6 may associate with its intracellular
localization (cytosol or nuclei) [15,38,39]. Nevertheless,
the role of PTK6 in the tumorigenesis of NPC has not
been explored, to date.
In this study, our aim was to detect the expression of
PTK6 in NPC, and identify whether PTK6 can be a po-
tential diagnostic and prognostic biomarker for NPC pa-
tients. To examine PTK6 mRNA and protein expression,
quantitative RT-PCR, Western blotting analysis and im-
munohistochemistry (IHC) methods were applied. Then
we analyzed the relationship of PTK6 expression and the
clinical factors as well as the prognosis of NPC patients.
In addition, overexpression PTK6 can enhance the pro-
liferation and colony formation ability in NPC cells. Fi-
nally, our findings indicate that high PTK6 expression
may play an important role in NPC progression and
serve as an independent prognostic biomarker for fore-
casting poor prognosis in NPC patients, peculiarly those
with advanced clinical stages.
Materials and methods
Nasopharyngeal patients and clinical tissue specimens
All clinical samples used for the expression of PTK6
studies by quantitative RT-PCR, and immunohistochem-
istry (IHC) assay were collected from Sun Yat-sen Uni-
versity Cancer Center (SYSUCC), Guangzhou, China. 31
NPC and 16 non-tumorous nasopharyngeal mucosa bi-
opsies were collected for quantitative RT-PCR assay dur-
ing 2011. Each biopsy specimen was immersed into the
RNA-Later reagent overnight at 4°C and then preserved
at −80°C prior to RNA extraction. For IHC analysis, 178
paraffin-embedded NPC specimens and 10 normal naso-
pharyngeal epithelial samples were collected between
2005 and 2007. The clinicopathological characteristics
are summarized in Table 1. All of these NPC patients
were treated with standard curative radiotherapy with or
without chemotherapy. Cancer TNM stage was defined
on the basis of the UICC (International Union Against
































Abbreviations NPC nasopharyngeal carcinoma, WHO World Health
Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC
non-keratinizing differentiated carcinoma, OS overall survival.
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Cancer). All the patients were followed from the date
of diagnosis until death or the lasted census date. The
Institute Research Medical Ethics Committee of Sun
Yat-Sen University granted approval for this study.
Cell lines and cell cultures
Two immortalized nasopharyngeal epithelial cell lines
(NPECs) induced by Bmi-1 (NPEC1 Bmi-1 and NPEC2
Bmi-1) were established as described previously and
cultured in keratinocyte serum-free medium (KSF,
Invitrogen, USA) [40,41]. The NPC cell lines including
CNE1, CNE2, 6-10B, 5-8F, HONE1 , SUNE1 and HNE1
were cultured in RPMI-1640 medium (Gibco, USA) with5% fetal bovine serum (Gibco, USA). All cell lines were
grown in a humidified incubator 37°C with 5% CO2.RNA extraction and quantitative RT-PCR analysis
Total RNA of NPC and non-tumorous nasopharyngeal
mucosa biopsies were extracted from the E.Z.N.A. total
DNA/RNA isolation kit according to manufacturer’s in-
structions (OMEGA bio-tek; R6731; USA). The RNA
from various cell lines was extracted as described previ-
ously [42]. RNA concentration and quantity were deter-
mined with NanoDrop spectrophotometer (ND-1000,
Thermo Scientific, USA). According to the manufac-
turer’s instructions, the first strand cDNA synthesis was
performed using 1 μg of total RNA and M-MLV reverse
transcriptase (Invitrogen, USA). We used iQ™ SYBR
Green Supermix to determine the threshold cycle (Ct)
value of each specimen in the CFX96 real-time PCR de-
tection system (Bio-Rad, CA, USA). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an
internal control for comparison and normalization in
these studies.






Quantitative RT-PCR amplifications were performed
under this condition: UDG incubation at 50°C for 2 min,
initial denaturation at 95°C for 2 min, denature at 95°C
for 15 s, anneal and extend at 60°C for 30 s; reaction
were carried out for 40 cycles. For data analysis, the rela-
tive expression levels of PTK6 were given by 2-△Ct,where
△Ct = Ct (unknown) - Ct (internal control).Western blotting analysis
Equal amounts of whole cell lysates were separated by
electrophoresis on a 10.5% SDS polyacrylamide gel
electrophoresis (PAGE) and electrotransferred on a
polyvinylidene difluoride (PVDF) membrane (Pall, Port
Washington, New York, USA). The membrane was
blocked with 5% skimmed milk for 1.5 hours (h). Then
we incubated the tissues with a primary rabbit polyclonal
antibody against human PTK6 (1:500 dilution; Abgent,
USA) overnight at 4°C. The proteins bands were visual-
ized using an enhanced chemiluminescent western blot
Kit (Amersham, UK). The membranes were stripped and
probed with a mouse monoclonal antibody against human
GAPDH (1:4000 dilution; Santa Cruz Biotechnology,
USA) to confirm equal loading of the samples.
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Formalin-fixed, paraffin-embedded NPC samples were
cut into 4-μm thick sequential sections. Then the sec-
tions were baked for 3 hours at 58°C. After being
deparaffinized in xylenes and rehydrated with graded al-
cohol to distilled water. We immersed these sections in
3% hydrogen peroxide for 10 min to block endogenous
peroxidase activity at room temperature, and then boiled
the sections in Citrate Antigen Retrieval Solution
(PH=6.0) for 5 min in a high-pressure cooker for antigen
retrieval. After the temperature of this retrieval solution
return to room temperature, the sections were incubated
with diluted rabbit polyclonal anti-PTK6 antibody (1:200
dilution;Abgent, USA) overnight at 4°C in a moist cham-
ber. The next day, after being washed in phosphate buff-
ered saline add Tween-20 (PBST), the sections were
incubated with a secondary antibody for 30 min at 37°C
and then washed in PBST twice, followed with a 2 min
staining in DAB (3,3-diaminobenzidine) for protein de-
tection. The sections were counterstained with Mayer’s
hematoxylin to stain nucleus and were finally dehydrated
and mounted. A negative control was obtained by re-
placing the primary antibody with a normal rabbit IgG.
Evaluation of IHC
The immunoreactivities were scored separately by two
pathologists blinded to the clinical parameters. Tumor
cell percentage were scored as follows: 0, negative or less
than 10% positive tumor cells; 1, 10-25% positive tumor
cells; 2, 26-60% positive tumor cells; 3, more than 60%
positive tumor cells. Staining intensity was categorized:
0, no staining; 1, weak staining; 2, moderate staining and
3, strong staining. The two individual parameters were
multiplied. Then we can get an immunoreactivity score
(IRS) ranging from 0 to 9. All results were confirmed by
at least 2 pathologists in a double-blind analysis. An op-
timal cut-off value for high and low expression was se-
lected on the basis of a measure of heterogeneity with
the log-rank test statistical analysis with respect to over-
all survival (OS). For PTK6, the optimal cutoff value was
determined: an IRS ≤5.0 defined tumors with low ex-
pression, and IRS > 5.0 indicated high expression.
Statistical analysis
Statistical analysis was performed using SPSS software,
version 17.0 (SPSS, Chicago, USA). The correlation be-
tween PTK6 expression and clinicopathological status of
NPC patients was assessed by chi-square test. Survival
curves for both PTK6 high-expression and PTK6 low-
expression patients were plotted using the Kaplan-Meier
analysis and log-rank test. Univariate and multivariate
regression analysis were performed with the Cox propor-
tional hazards regression model to determine the effect
of particular prognostic factors on survival. A P-valueless than 0.05 was considered as statistically significant
in all cases.
Plasmids and transient transfection
The full-length human PTK6 was cloned into
pcDNA3.1 vector with BamHI site and EcoRI site.
HNE1 cells (2.5×105) were seeded in 6-well plates at
60% confluence, and then transient transfected with
pcDNA3.1 empty vector or pcDNA3.1-PTK6 plasmid
using Lipofectamine 2000 (Invitrogen, USA) according
to the instructions provided by the manufacturer.
After six hours incubation at 37°C with 5% CO2, the
transfection medium was replaced with 2 ml fresh cul-
ture medium. Cells were collected for western blot-
ting, quantitative RT-PCR, proliferation and colony
formation assays at 36 hours post-transfection.
Cell proliferation assay and colony formation assay
MTT (methyl thiazolyl tetrazolium, Sigma-Aldrich, USA)
assay was used to determine cell proliferation. For MTT
assay, HNE1-pcDNA3.1-vector (control) cells and HNE1-
pcDNA3.1-PTK6 (PTK6 overexpression) cells were cultured
in 96-well plates at an initial density of 1×103. Then the
MTT solution (20 μl, 5 mg/ml in PBS) was added directly
into each well and the cells were incubated at 37°C for 4
hours. The medium was removed and 200 μl of DMSO (di-
methyl sulfoxide) was added to each well. After 10 minutes
of vibration mixing, the optical density (OD) was measured
at 570 nm with a microplate reader. The OD value of cell
numbers were measured every 24 hours from the first day
(day 1) to the fifth day (day 5). The experiment was repeated
three times.
For colony formation assay, cells were plated at a density
of 200 cells/well in six-well plates, and cultured with RPMI-
1640 medium with 5% fetal bovine serum for 9 days. The
medium was changed every 3 day for 9 days until most vis-
ible colonies had expanded with more than 50 cells. Col-
onies were simultaneously fixed in methanol for 10 min,
and stained with crystal violet for 10 min. After washing out
the dye, the colonies were manually counted and the plates
were photographed. Three independent experiments were
carried out for the assay.
Results
The expression of PTK6 in NPC cell lines and fresh
biopsies
To examine the expression pattern of PTK6 in NPC, we first
performed a western blotting analysis using a monoclonal
antibody against PTK6 on 6 NPC cell lines including CNE1,
CNE2, 6-10B, 5-8F, HONE1, SUNE1, and HNE1 and two
immortalized nasopharyngeal epithelial cells (NPEC1 Bmi-1
and NPEC2 Bmi-1). The expression of PTK6 protein was
barely observed in the non-tumorous cells. However, most
of the NPC cell lines showed highly expression levels of
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line (Figure 1A and B). To evaluate whether the enhanced
PTK6 expression was occurred at transcriptional level, we
performed a quantitative RT-PCR analysis on the same cell
lines. Consistently, most of NPC cell lines determined ex-
cept HNE1 showed higher expression of PTK6 mRNA than
that in non-tumorous cells (Figure 1C). To further examine
whether the high expression of PTK6 occurred in NPC pa-
tients, we performed quantitative RT-PCR on 31 fresh NPC
biopsies and 16 non-tumorous nasopharyngeal epithelial bi-
opsies. As shown in Figure 1C, unlike to the low PTK6
mRNA expression in all of the non-tumorous biopsies, NPC
tissues showed a various expression level of PTK6 mRNA.
The mean expression level in NPC tissues is significantly
higher than the level in non-tumorous tissues (Figure 1D).
In conclusion, PTK6 was upregulated in NPC cell lines and
also in some NPC tissues.
PTK6 Expression in NPC and normal nasopharyngeal
epithelial tissues by IHC analysis
To examine the expression pattern of PTK6 in archive
NPC tissues, we performed the IHC analysis with the spe-









































































Figure 1 Expression of PTK6 in cell lines and nasopharyngeal tissues.
CNE1, CNE2, 6-10B, 5-8F, HONE1 and SUNE1 than in Bmi-1/NPEC1 and Bmi
protein as mean (±SD) by normalizing to the expression of GAPDH. n=thre
in those 6/7 NPC cell lines presented higher mRNA expression level of PTK
The mRNA expression levels of PTK6 from 31 NPC patients and 16 non-tumepithelial tissues. The representative results of IHC are
shown in Figure 2. In our study, we observed no staining
in these 10 cases of normal nasopharyngeal epithelial tis-
sue (Figure 2A and B). However, among the 178 cases of
NPC, we observed staining of PTK6 in almost all NPC ex-
cept one sample (Figure 2C and D). Among them, 27
(15.2%) cases showed weak intensity (Figure 2E and F), 62
(34.8%) cases showed moderate staining (Figure 2G and
H), and 88 (49.4%) cases showed strong intensity (Figure 2I
and J). The IRS was multiplied by the score of tumor cell
percentage and the score of staining intensity as we de-
scribed before. We also found that PTK6 were largely lo-
calized in the cytoplasm of NPC cells.
Association of PTK6 expression with clinicopathological
features and Cox proportional hazards survival analysis
To determine whether the PTK6 expression was corre-
lated with clinical pathological characteristics, all the
samples were separated into either low or high PTK6 ex-
pression groups, on the basis of their expression levels
according to the cutoff score [43]. In our study, the cut-
off score for the expression of PTK6 was set at 5.0. As a































































(A) PTK6 expression was higher in most of NPC cell lines include
-1/NPEC2 by Western blot analysis. (B) Quantitative analysis of PTK6
e different experiments. (C) Quantitative RT-PCR detection showed that
6 than that in those two NPECs. n=three independent experiments. (D)










Figure 2 Expression of PTK6 in NPC tissues by immunohistochemistry staining. (A and B) negative PTK6 staining in normal nasopharyngeal
epithelium tissue (negative control) (A) 200X, (B) 400X; (C and D) negative staining of PTK6 in NPC tissue (C) 200X, (D) 400X; (E and F) weak
staining of PTK6 in cytoplasm (E) 200X, (F) 400X; (G and H) moderate staining of PTK6 in cytoplasm (G) 200X, (H) 400X; (I and J) strong staining of
PTK6 in cytoplasm (I) 200X, (J) 400X.
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nated as low expression. High expression level of PTK6
was observed in 113/178 (63.5%) of NPC samples. PTK6
expression was significantly associated with tumor size
(T classification) (P<0.001, Table 2), clinical stage
(P<0.001, Table 2), and metastasis (P=0.016, Table 2) in
those all NPC patients; however, there was no significant
correlation between PTK6 expression and other clinico-
pathological features, such as patient age, sex, lymphoid
nodal states (N classification), local-regional relapse, and
WHO classification (P>0.05, Table 2).
Univariate Cox proportional hazard regression analysis
showed that PTK6 expression (P<0.001), age (P=0.003),
metastasis (P<0.001), local-regional relapse (P=0.017),
lymphoid nodal states (N classification) (P=0.039) and
clinical stage (P=0.003) were significantly associated
with five-year overall survival (Table 3). The features
were also significant in a multivariate Cox proportional
hazards regression model (Table 3). After multivariate
adjustment for above significant clinicopathological fea-
tures, PTK6 was an independent and unfavorable factor
(HR: 2.038; 95% confidence interval: 1.051-3.951;
P=0.035). In addition, age (HR: 1.900; 95% confidence
interval: 1.165-3.079; P=0.010), metastasis (HR: 5.290;
95% confidence interval: 3.122-8.962; P<0.001), local-
regional relapse (HR: 2.427; 95% confidence interval:
1.303-4.519; P=0.005) and clinical stage (HR: 3.343; 95%confidence interval: 1.057-10.574; P=0.040), respectively,
were defined as independent prognostic predictors for
five-year overall survival (Table 3).
Correlation of PTK6 expression and overall survival
The five-year OS rate of the cohort of 178 NPC patients
was 53.9% (Figure 3A). The prognostic value of PTK6
was evaluated through estimation of OS using Kaplan-
Meier and log-rank test analyses. The result showed that
high PTK6 expression was significant related to poor OS
compared to low PTK6 expression (47.8% versus 80.0%,
P<0.001, Figure 3B). Next, we stratified the clinical
stages into two groups that include early stages (I + II)
and advanced stages (III + IV), and found that the asso-
ciation between high PTK6 expression and shorter OS
were significantly stronger in patients at advanced stages
than in early stages. In the advanced stages, the 5-year
OS rate of late stages patients with high or low expres-
sion of PTK6 was 42.2% or 79.1%, respectively (P<0.001,
Figure 3C). However, in the earlier stages, the 5-year OS
rate was 100% and 81.8% among high expression and
low expression patients (P=0.151, Figure 3D).
Overexpression of PTK6 in NPC cell line HNE1
HNE1 NPC cells containing relatively lower endogenous
PTK6 levels were transfected with pcDNA3.1-PTK6 to
achieve overexpression of PTK6. At 36 hours post-
Table 2 Correlation between PTK6 expression and clinicopathologic characteristics in NPC cases
Characteristics PTK6 expression P-value
Low (n = 65) (%) High (n = 113) (%)
Age (years)
≤46 39 (60.0) 60 (53.1)
>46 26 (40.0) 53 (46.9) 0.434
Sex
Female 14 (21.5) 31 (27.4)
Male 51 (78.5) 82 (72.6) 0.474
Tumor size
T1+T2 33 (50.8) 25 (22.1)
T3+T4 32 (49.2) 88 (77.9) <0.001*
Lymphoid nodal states
N0-1 34 (52.3) 58 (51.3)
N2-3 31 (47.7) 55 (48.7) 1.000
Clinical stage
I+II 22 (33.8) 11 (9.7)
III+IV 43 (66.2) 102 (90.3) <0.001*
Local-regional relapse
Yes 6 (9.2) 17 (15.0)
No 59 (90.8) 96 (85.0) 0.355
Metastasis
Yes 6 (9.2) 27 (23.9)
No 59 (90.8) 86 (76.1) 0.016*
WHO histological classification
NKUC 62 (95.4) 107 (95.6)
NKDC 3 (4.6) 6 (4.5) 0.748
*Statistically significant difference.
Abbreviations NPC nasopharyngeal carcinoma, PTK6 protein tyrosine kinase 6, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma,
NKDC non-keratinizing differentiated carcinoma.
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PTK6 were higher in PTK6-overexpression cells com-
pared to the control cells transfected with empty vector
by quantitative RT-PCR and western blot analysis, re-
spectively (Figure 4A and 4B).
PTK6 Enhances the proliferation and colony formation
ability of NPC cells
To investigate the effect of PTK6 on cellular prolifera-
tion in HNE1 cells, the MTT assay was performed after
overexpressing PTK6. As shown in Figure 4C, the
growth curves from the day 1 to 5 demonstrated that
HNE1 cells with overexpression of PTK6 grew faster
than control cells, suggesting that overexpression of
PTK6 can enhance the proliferation of the NPC cells.
Then we explored the colony formation ability of
PTK6-overexpressed HNE1 by the colony formation
assay, and found that PTK6-overexpression cells formed
more colonies than those of the control cells (Figure D,upper panel). There is a significant differences in the
number of colonies between the vector control cells and
the PTK6-expression cells (P=0.0017; Figure D, lower
panel).
Discussion
NPC is a malignant tumor that originates from the
upper lining and lateral wall of nasopharynx. Approxi-
mately 70% of NPC patients often diagnosed at late
stages when the time of diagnosis, leading to a high rate
of local-regional relapse and metastasis after radiother-
apy alone [44,45]. NPC high death rate is mainly due to
tumor metastasis despite the new treatment that com-
bining radiotherapy with chemotherapy [46]. Therefore,
novel molecular biomarkers for confirming tumor me-
tastasis and predicting prognosis to improve the cure
rate are eagerly needed.
In our study, we observed a high expression of PTK6
in most NPC cell lines include CNE1, CNE2, 6-10B, 5-
Table 3 Univariate and multivariate Cox regression analysis of different prognostic variables in NPC patients
Variable Subset HR (95%) CI P-value
Univariate analysis (N=178)
PTK6 expression High versus Low 3.519 (1.918-6.458) <0.001*
Age (years) > 46 versus ≤ 46 2.046 (1.278-3.277) 0.003*
Sex Female versus Male 0.872 (0.512-1.485) 0.614
Metastasis Yes versus No 4.735 (2.919-7.679) <0.001*
Local-regional relapse Yes versus No 1.999 (1.129-3.539) 0.017*
Tumor size T1+T2 versus T3+T4 1.477 (0.872-2.502) 0.147
Lymphoid Nodal states N0-1 versus N2-3 1.657 (1.072-2.672) 0.039*
Clinical stage I + II versus III + IV 4.599 (1.676-12.619) 0.003*
WHO histological classification NKDC versus NKUC 1.244 (0.404-3.834) 0.703
Multivariate analysis (N=178)
PTK6 expression High versus Low 2.038 (1.051-3.951) 0.035*
Age (years) > 46 versus ≤ 46 1.900 (1.165-3.079) 0.010*
Metastasis Yes versus No 5.290 (3.122-8.962) <0.001*
Local-regional relapse Yes versus No 2.427 (1.303-4.519) 0.005*
Lymphoid Nodal states N0-1 versus N2-3 1.372 (0.823-2.288) 0.225
Clinical stage I + II versus III + IV 3.343 (1.057-10.574) 0.040*
*Statistically significant difference
Abbreviations PTK6 protein tyrosine kinase 6, NPC nasopharyngeal carcinoma, HR hazard ratio, CI confidence interval.
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level, but not in a highly differentiated NPC cell line
HNE1, NPEC1 Bmi-1 or NPEC2 Bmi-1 cells. The
mRNA level of PTK6 expression are higher in NPC bi-
opsy samples than in non-tumorous nasopharyngeal mu-
cosa biopsies. Moreover, the IHC result showed that
PTK6 was not expressed in normal nasopharyngeal epi-
thelium, but presented an increased expression in most
NPC samples. Taken together, it suggested that PKT6
might play an important role in NPC.
Furthermore, the high expression of PTK6 was signifi-
cantly correlated to tumor size (T classification), clinical
stage, and metastasis, respectively (P<0.05, Table 2). We
also showed that high expression of PTK6 was associ-
ated with poor 5-year overall survival rate of NPC
(P<0.001, Figure 3B). Moreover, compared to the early
stages, a strong correlation between high PTK6 expres-
sion and short survivals was found at advanced stages
(P<0.001, Figure 3A and D), indicating that PTK6 might
involve in progression and metastasis of NPC. These
findings are in accordance with some previous reports,
such as breast cancer [47,48], non-small cell lung cancer
[33], ovarian cancer [31], colon cancer [20], head and
neck cancers [32] and metastatic melanoma cells [34].
Since tumor metastasis is the major cause of advanced
NPC, it is urgent to identify a biomarker for diagnosis of
NPC and find a potential therapy target for NPC metas-
tasis. In the current study, we showed that a high ex-
pression of PTK6 in most of NPC cell lines and NPCtissue samples, suggested that PTK6 may serve as a bio-
marker for advanced stages patients and as a possible
therapy factor. Multivariate Cox proportional hazards
survival analysis indicated that high PTK6 expression in
NPC tumor tissues was an independent and unfavorable
factor for poor prognosis of NPC patients (P=0.035,
Table 3). We also confirmed that advanced increased age
(P=0.010), metastasis (P<0.001), local-regional relapse
(P=0.005), and advanced clinical stage (P=0.004) were
the independent predictive factors for survival, these re-
sult were consistent with previous studies [49-51]. All
the results suggested that PTK6 could be a useful bio-
marker for the prognosis and metastasis of NPC.
PTK6 has a structural homology with c-Src-family
tyrosine kinase and consists of a tyrosine kinase domain
that is subject to autophosphorylation and autoinhibition,
as well as SH2 and SH3 domains that are implicated in
protein interactions and autoregulation. However, distinct
from c-Src, PTK6 lacks an N-terminal SH4 domain re-
quired for fatty acid acylation and membrane localization,
thereby rendering that PTK6 could locate in both cyto-
plasmic and nuclear compartments. Soluble PTK6 seems
to play an important role in mediating signaling pathways
and many aspects of cell biology across different cellular
contexts. Taken together, these suggest that the functions
of PTK6 depend on not only cell types, but also its intra-
cellular localization. The location of PTK6 is variable in
different cells. Schmandt RE et al. used IHC to demon-
strate that PTK6 was high expressed in 70% of the ovarian






















































Overall survival rate of
different PTK6 level
Early stage Advanced stage
Figure 3 Kaplan-Meier survival curve and log-rank test analysis showing the association between PTK6 expression and NPC patient
survival. (A) The five-year overall survival (OS) rate was 53.9% of 178 NPC patient; (B) High PTK6 expression level was significantly correlated to
OS (P<0.001) in all NPC patients. (C) Cases were stratified by clinical stage. No significant difference in five-year OS rate was found between PTK6
high-expression and low-expression in NPC patients at early stages (StageI+II); (D) High PTK6 expression level was significantly associated with OS
(P<0.001) in NPC patients at late stages (Stage III+IV).
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ovarian. The also found that PTK6 primarily located at
the cytoplasm of ovarian cancer cells, however, in a subset
of tumor cells, staining was observed in the nuclei [31].
Fan, C et al. also found the similar results, they found the
expression of PTK6 was significantly higher in cytoplasm
of NSCLC compared to in the nuclei. Furthermore, the
cytoplasmic expression of PTK6 in normal lung tissue
cells was lower than that in NSCLC [33]. Interesting, it is
reported that PTK6 is located in the nuclei of normal
prostate epithelium and well-differentiated prostate tumor,
but it is located in the cytosol of poorly differentiated
prostate carcinoma [19]. Recently, Ma et al. identified
PTK6 mRNA expression was significantly reduced in
esophageal squamous cell carcinoma (ESCC) due to epi-
genetic modification and work as a tumor suppressor via
in vivo and in vitro studies. Unlike in the cases for ovarian
cancer, NSCLC and prostate carcinoma, the found PTK6
located in both cytoplasm and nuclei fractions in ESCC[18]. In our study, PTK6 was found to be located primarily
in cytoplasmic compared to in the nuclei fractions in
NPC, this result was similar with the previous study of the
expression of PTK6 in ovarian carcinoma, NSCLC and
poorly differentiated prostate cacinoma [19,31,33]. It has
been suggested that nuclear PTK6 is possibly related to
growth regulation in normal epithelium; however, cyto-
plasmic PTK6 may activate oncogenic signaling pathways
[19,52]. So, a large scale of clinical investigation and fur-
ther experimental study are still necessary to elucidate the
exact role of PTK6 in NPC.
It is reported that PTK6 has been demonstrated to link
with cellular differentiation, apoptosis, migration and
wound healing in normal epithelium. However, PTK6
also participates in cancer progression by sensitizing
cells to mitogenic signals, enhancing proliferation, mi-
gration/invasion, and anchorage-independent survival in
tumor tissues [53]. Interesting, according to several










Figure 4 PTK6 overexpression simulates the proliferation and transforming ability of NPC cells. (A) PTK6 overexpression in HNE1 cells at
36 hours post-transfection. HNE1 cells were transfected with pcDNA3.1-PTK6 and the control plasmid pcDNA3.1-empty vector, respectively. A
dramatically increased mRNA level of PTK6 was detected in pcDNA3.1-PTK6 transfected cells by quantitative RT-PCR. (B) Western blotting analysis
showed that the protein level of PTK6 in HNE1 cells after transfection. (C) The growth curves of HNE1 cell line. After transient transfection of PTK6,
the PTK6-overexpression cells grew significantly faster than control cells from day 2 to day 5 (P<0.001, marked by *). Error bar =SD. (D)
Representative pictures of colony formation assay of the HNE1 cell line transfected with pcDNA3.1-PTK6 and the control plasmid pcDNA3.1-
empty vector. Upon the transient transfection expression of PTK6, HNE1 cells formed more colonies compared to the control cells. Error bar =SD.
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anchorage-independent growth, cell migration, and tumor
growth in breast cancer models. Nevertheless, it has been
suggested that a significant correlation between PTK6 and
the estrogen receptor as well as overexpression of PTK6
corresponds to better prognosis [54,55], these provides
evidence for that PTK6 may associate with the cell type
and degree of differentiation of cancer cells in breast tu-
mors. It is appeared that different expression patterns of
ligands, receptors, as well as PTK6 substrates and binding
partners affect the specificity of PTK6 action. In our study,
the results of MTT assay and colony formation assay
showed that overexpression of PTK6 can enhance cell
proliferation and colony formation ability and high ex-
pression of PTK6 cause poor prognosis in NPC. However,
the mechanism of the function of PTK6 in NPC is still un-
known. Further studies are needed to characterize the ap-
parent context- and tissue-specific functions of PTK6 in
both normal tissues as well as tumors and clarify the con-
tributions of PTK6 to initiation and progression of epithe-
lial cancers.Shen et al. showed that PTK6 induced tumor prolifer-
ation, invasion and migration by triggering EGF-
mediated phosphorylation of p190RhoGAP, leading to
Ras activation and RhoA inactivation in MDA-MB231
breast cancer cells [56]. Moreover, it has been reported
that high expression level of EGFR was significantly as-
sociated with T stages, clinical stages, local recurrence,
and poor prognosis of the NPC patients [12,57,58]. Fur-
thermore, PTK6-induced paxillin phosporylation pro-
moted Rac activation via CrkII and cellular migration
and invasion [59]. Additionally, kinesin-2 subunit KAP3A
was necessary for cell migration promoted by PTK6 [60].
Carol et al. demonstrated that PTK6 mediated HGF/
MET-induced cell migration in breast cancer [48,53,61].
Interestingly, it is well known that overexpression of Met
was a poor prognosis biomarker of NPC, correlated with
lymph node metastasis, and its aberrant activation de-
pends on paracrine HGF from stoma cells rather than an
autocrine loop or activating mutation [62-64]. Based on
our results, PTK6 was significantly associated with T clas-
sification, clinical stage and metastasis in NPC. In
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eration and colony formation ability, suggesting that
PTK6 might play an important role in NPC progression
and metastasis, probably through sustaining and activating
EGF pathway or through the activation of downstream
pathways of HGF/MET in NPC. Therefore, we will deeply
investigate the mechanisms underlying PTK6-mediated
progression and metastasis of NPC in the future study, by
identifying the receptor, adapters and target proteins and
pathways of PTK6.
Conclusion
In summary, we observed the highly expressed PTK6 in
NPC and overexpression of PTK6 contributed increases
in cell proliferation and colony formation ability of NPC
cells, and demonstrated that high level of PTK6 is closely
correlated with poor prognosis of NPC, suggesting that
PTK6 may serve as a useful biomarker to determine the
prognosis of NPC and provide a potential therapeutical
target for NPC treatment.
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